Posts Tagged ‘Philip Johnson’

charles craddock

June 10th, 2010

Some kinds of leukemia and myeloma have been traditionally very difficult to treat, and put patients through punishing chemotherapy which only sometimes worked. This situation has recently changed dramatically.

Charles Craddock Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust says there are now exciting novel transplant and drug therapies, transforming patients’ lives, enabling many to live longer and fuller lives than was ever thought possible only a few years ago.

Charles Craddock is Professor of Haematolo-oncology at the University of Birmingham as well as Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust. He has a particular research interest in the development of novel transplant and drug therapies in leukemia and myeloma. He also works with groups researching chromatin structure in acute-myeloid leukemia, mechanisms of drug resistance in myeloma and characterisaation of dysregulated signalling pathways in leukemia using proteomics.

philip johnson

June 10th, 2010

“The UK is the best place in the world to run trials, with consequent ‘wealth and health’ benefits,” so says Philip Johnson, Director of the Cancer Research UK Clinical Trails Unit as well as Professor of Oncology and Translational Research at the University of Birmingham. In The New Optimists he argues why clinical trials are so important, and the kind of impact they have on treatments and patient care across the world.

Professor Johnson developed his interest in clinical trials and hepatobiliary cancer whilst at the Institute of Liver Studies, Kings College Hospital, London where he subsequently became Assistant Director. In 1992, he was appointed to the Chair of Clinical Oncology at the Chinese University of Hong Kong where he also became Director of the Cancer Centre and developed the Comprehensive Clinical Trials Unit whilst furthering his research interests into molecular biomarkers of cancer and new approaches to the treatment of live cancer.